Review: Thinking around abdominal obesity and cardiovascular risk

Abstract

Obesity, particularly intra-abdominal (visceral) obesity, is a leading cause of cardiovascular disease (CVD), insulin resistance, type 2 diabetes, dyslipidaemia, inflammation and thrombosis. A useful indicator for visceral fat is waist circumference, which is associated with all-cause mortality. Pro-inflammatory adipokines play a causal role in the development of pathologies associated with insulin resistance, type 2 diabetes and CVD. In addition to established anti-obesity therapies, namely orlistat and sibutramine, a new type of agent that inhibits the cannabinoid receptor (CB1) is advanced in development to reduce appetite and act predominantly against intra-abdominal adiposity.

Keywords

abdominal obesity metabolic syndrome visceral fat waist circumference cardiometabolic risk.

Get full access to this article

View all access options for this article.

References

York DA , Rossner S. , Caterson I. et al. Obesity, a worldwide epidemic related to heart disease and stroke group I: worldwide demographics of obesity. Circulation 2004;110:e463-70.

Emery EM , Schmid TL , Kahn HS et al. A review of the association between abdominal fat distribution, health outcome measures, and modifiable risk factors. Am J Health Promot 1993;7:342-53.

Despres JP , Lemieux I. , Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients . BMJ 2001;322:716-20.

Eckel RH , Grundy SM , Zimmet PZ The metabolic syndrome. Lancet 2005;365:1415-28.

Stumvoll M. , Goldstein BJ , van Haeften TW Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46.

International Diabetes Federation. The IDF worldwide definition of the metabolic syndrome. Launched 14 April 2005. Accessible via http://www.idf.org/home/index.cfm?unode=32EF2063-B966-468F-928C-A5682A4E3910(accessedSept2005).

Alberti KG , Zimmet P. , Shaw J. ; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.

Reaven GM The metabolic syndrome: requiescat in pace. Clin Chem 2005;51:931-8.

Day C. Diagnostic definitions - metabolic syndrome. Br J Diabetes Vasc Dis 2005;5:115-18.

10.

Klein S. The case of visceral fat: argument for the defense. J Clin Invest 2004;113:1530-2.

11.

Pouliot MC , Despres JP , Lemieux S. et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-8.

12.

Bigaard J. , Frederiksen K. , Tjonneland A. et al. Waist and hip circumferences and all-cause mortality: usefulness of the waist-to-hip ratio? Int J Obes Relat Metab Disord 2004;28:741-7.

13.

Kannel WB , Cupples LA , Ramaswami R. et al. Regional obesity and risk of cardiovascular disease: the Framingham Study. J Clin Epidemiol 1991;44:183-90.

14.

Yusuf S. , Hawken S. , Ounpuu S. et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.

15.

Ritchie SA , Ewart MA , Perry CG et al. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (Lond) 2004;107:519-32.

16.

Perry C. , Sattar N. , Petrie J. Adipose tissue : passive sumper active pump. Br J Diabetes Vasc Dis 2001;1:110-14.

17.

Lau DC , Dhillon B. , Yan H. et al. Adipokines: molecular links between obesity and atherosclerosis . Am J Physiol Heart Circ Physiol 2005;288: H2031-41.

18.

Arner P. Insulin resistance in Type 2 diabetes - role of the adipokines. Curr Mol Med 2005;5:333-9.

19.

Wajchenberg BL Subcutaneous and visceral adipose tissue: theirrelation to the metabolic syndrome. Endocr Rev 2000;21:697-738.

20.

Fasshauer M. , Paschke R. Regulation of adipocytokines and insulin resistance . Diabetologia 2003;46:1594-603.

21.

Trayhurn P. The biology of obesity. Proc Nutr Soc 2005;64:31-8.

22.

Hansson GK Inflammation, atherosclerosis, and coronary artery disease. NEJM 2005;352:1685-95.

23.

3. Stewart KJ , Bacher AC , Turner K. et al. Exercise and risk factors associated with metabolic syndrome in older adults. Am J Prev Med 2005;28:918.

24.

McAuley KA , Hopkins CM , Smith KJ et al. Comparison of high-fat and high-protein diets with a high-carbohydrate diet in insulin-resistant obese women. Diabetologia 2005;48:8-16.

25.

Pirozzo S. , Summerbell C. , Cameron C. et al. Advice on low-fat diets for obesity. Cochrane Database Syst Rev 2002;2:CD003640.

26.

Norris SL , Zhang X. , Avenell A. et al. Long-term non-pharmacologic weight loss interventions for adults with Type 2 diabetes. Cochrane Database Syst Rev 2005;2:CD004095.

27.

Pagotto U. , Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid Type 1 receptors. Lancet 2005;365:1363-4.

28.

National Obesity Forum (NOF) Guidelines: Appendix 2 - Accessible via www.nationalobesityforum.org.uk (accessed Sept 2005 ).

29.

NICE Technology Appraisal Guidance - No. 22: Guidance on the use of orlistat for the treatment of obesity in adults. March 2001.

30.

NICE Technology Appraisal Guidance - No. 31: Guidance on the use of sibutramine for the treatment of obesity in adults. October 2001.

31.

Bailey CJ , Day C. New pharmacological approaches to obesity. Obesity in Practice 2005;1:2-5.

32.

Sjostrom L. , Rissanen A. , Andersen T. et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-72.

33.

Day C. , Bailey CJ Sibutramine update. Br J Diabet Vasc Dis 2002 ;2:392-7.

34.

James WP , Astrup A. , Finer N. et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-25.

35.

Finer N. , Pagotto U. The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management. Br J Diabet Vasc Dis 2005 ;5:121-4.

36.

Di Marzo V. , Goparaju SK , Wang L. et al.Leptin-regulated endocannabi-noids are involved in maintaining food intake. Nature 2001;410:822-5.

37.

Bensaid M. , Gary-Bobo M. , Esclangon A. et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63:908-14.

38.

Rinaldi-Carmona M. , Barth F. , Heaulme M. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350:240-4.

39.

Ravinet Trillou C. , Arnone M. , Delgorge C. et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003;284:R345-53.

40.

Cota D. , Marsicano G. , Tschop M. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-31.

41.

Ravinet Trillou C. , Delgorge C. , Menet C. et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28:640-8.

42.

Poirier B. , Bidouard JP , Cadrouvele C. et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005;7:65-72.

43.

Van Gaal LF , Rissanen AM , Scheen AJ et al. RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.

44.

Pi-Sunyer FX Effect of rimonabant on weight reduction and weight maintenance: RIO North America (RIO-NA) trial. Circulation 2005; 111:1727.